 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Hana Biosciences, Inc.
|
-
Hana Biosciences annouces vice president appointments in clinical operations and corporate development
(01/09/2007)
Hana Biosciences announced the promotion of Gavin S. Choy, Pharm.D. and Alex Tkachenko, Ph.D. In their new roles, Dr. Choy will be responsible for all clinical operations as Vice President, Clinical Operations, while Dr. Tkachenko gains added ...
-
Commencement of INX-0125 Phase 1 Clinical Trial Triggers US$1.0 Million Milestone Payment to INEX
(09/01/2006)
Inex Pharmaceuticals Corporation announced that its partner Hana Biosciences has enrolled the first patient in a Phase 1 human clinical trial evaluating the safety, tolerability and preliminary efficacy of INX-0125 (sphingosomal vinorelbine) as a ...
-
Hana Biosciences receives orphan drug designation for cancer drug Ropidoxuridine
(06/13/2006)
Hana Biosciences announced that the U.S. Food and Drug Administration has granted orphan drug designation for Ropidoxuridine (IPdR) for the treatment of malignant glioma, which makes up approximately half of all primary brain tumors. Ropidoxuridine ...
-
Hana Bioscience receives orphan drug designation for Talotrexin for the treatment of acute lymphoblastic leukemia
(05/24/2006)
Hana Biosciences announced that the U.S. Food and Drug Administration has granted orphan drug designation for Talotrexin (PT-523) in patients with acute lymphoblastic leukemia (ALL). Talotrexin, a novel nonpolyglutamatable antifolate drug, is ...
-
Inex Pharmaceuticals Closes Hana Biosciences Licensing Agreement
(05/10/2006)
Inex Pharmaceuticals Corporation announced that it has closed the previously announced transaction to license three products from its Targeted Chemotherapy pipeline to Hana Biosciences, Inc. INEX has granted Hana a worldwide license to develop and ...
-
Hana Bioscience to license three targeted cancer drug candidates from Inex Pharmaceuticals
(03/21/2006)
Hana Biosciences signed a letter of intent to license the worldwide rights to develop and commercialize three novel targeted chemotherapy drug candidates for the treatment of solid and hematological cancers from Inex Pharmaceuticals Corporation. The ...
-
Hana Biosciences announces issuance of Talotrexin patent
(02/20/2006)
Hana Biosciences, a biopharmaceutical company focused on advancing cancer care, announced the issuance of U.S. Patent No. 6,989,386 from the U.S. Patent and Trademark Office. U.S. Patent No. 6,989,386 is directed to Talotrexin compositions and ...
|
|
|
|
|
Top
